Ngo Hoang Hai, Yu Bo-Yeong, Lee Jeong-Eun, Kim Hyunwoo, Keum Young-Sam
College of Pharmacy and Integrated Research Institute for Drug Development, Dongguk University, 32 Dongguk-Ro, Goyang, 10326, Gyeonggi-Do, Korea.
Arch Pharm Res. 2025 Aug 15. doi: 10.1007/s12272-025-01557-x.
NRF2 is a redox-sensitive transcription factor that activates the expression of phase II detoxifying and antioxidant enzymes. In addition to maintaining redox homeostasis, NRF2 regulates various other processes, including metabolism, stem cell renewal, mitochondrial function, and proteostasis. NRF2 is considered a tumor suppressor because its activation by chemopreventive phytochemicals contributes to the detoxification of oxidants and electrophiles in normal cells. However, aberrant NRF2 activation occurs in cancer due to mutations in the KEAP1/NRF2 pathway, and it contributes to the generation of a tumor microenvironment that favors the proliferation, survival, and chemoresistance of cancer cells. In this review, we present the regulatory mechanisms of NRF2 and discuss how NRF2 activation contributes to chemoresistance. We also explain therapeutic strategies that exploit the vulnerabilities of NRF2-addicted cancer cells, providing NRF2 small-molecule inhibitors along with their mechanisms of action.
NRF2是一种对氧化还原敏感的转录因子,可激活II期解毒酶和抗氧化酶的表达。除了维持氧化还原稳态外,NRF2还调节各种其他过程,包括代谢、干细胞更新、线粒体功能和蛋白质稳态。NRF2被认为是一种肿瘤抑制因子,因为化学预防植物化学物质对其激活有助于正常细胞中氧化剂和亲电子试剂的解毒。然而,由于KEAP1/NRF2途径的突变,癌症中会出现异常的NRF2激活,并且它有助于产生有利于癌细胞增殖、存活和化疗耐药性的肿瘤微环境。在这篇综述中,我们介绍了NRF2的调控机制,并讨论了NRF2激活如何导致化疗耐药性。我们还解释了利用对NRF2成瘾的癌细胞的脆弱性的治疗策略,提供了NRF2小分子抑制剂及其作用机制。